AR056418A1 - Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento - Google Patents

Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento

Info

Publication number
AR056418A1
AR056418A1 ARP060102971A ARP060102971A AR056418A1 AR 056418 A1 AR056418 A1 AR 056418A1 AR P060102971 A ARP060102971 A AR P060102971A AR P060102971 A ARP060102971 A AR P060102971A AR 056418 A1 AR056418 A1 AR 056418A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
optionally substituted
independently
attached
Prior art date
Application number
ARP060102971A
Other languages
English (en)
Inventor
Timothy D Owens
Steven Sethofer
Keith Adrian Murray Walker
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37054633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056418(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR056418A1 publication Critical patent/AR056418A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/38Oxygen atoms in positions 2 and 3, e.g. isatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de bencimidazol, un método para la obtencion de los mismos, composiciones que contienen dichos compuestos y métodos para el uso de los compuestos de la formula (1) para preparar un medicamento. Los compuestos son utiles para tratar enfermedades del SNC como el Parkinson y la ansiedad. Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptable de los mismos, en la que: m es un numero 0 a 3; n es 1 o 2; X es: -NRa-; -O-; -S-; -CRbRc-; o -C(O)- ; en los que: Ra es hidrogeno o alquilo; Rb es hidrogeno, fluor o alquilo; Rc es hidrogeno, fluor, alquilo, hidroxi; o alcoxi; o Rb y Rc juntos forman oxo; o Rb y Rc junto con el átomo de carbono al que están unidos pueden formar un anillo de tres a seis eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo elegido entre O, N y S; Ar es: arilo opcionalmente sustituido; o heteroarilo opcionalmente sustituido; R1 es un grupo de la formula (2); p es un numero de 1 a 4; Y es: -O-; -NRd-; o -CReRf-; en los que Rd, Re y Rf con independencia entre sí son hidrogeno o alquilo; cada R2 con independencia de su aparicion es: halogeno; alquilo; haloalquilo; haloalcoxi; alcoxi; heteroalquilo; ciano; -(CH2)q-S(O)r-Rg; -(CH2)q-C(=O)- NRhRi; -(CH2)q-SO2-NRhRi; -(CH2)q-N(Rj)-C(=O)-Rk, o -(CH2)q-C(=O)-Rk; en los que: q es 0 o 1; r es un numero de 0 a 2; y Rg, Rh, Ri y Rj con independencia entre sí son hidrogeno o alquilo, y Rk es hidrogeno, alquilo, alcoxi o hidroxi; R3 y R4 con independencia entre sí son hidrogeno o alquilo; R5 y R6 con independencia entre sí son hidrogeno o alquilo; y R7 y R8 con independencia entre sí son hidrogeno o alquilo; o R7 y R8 junto con el átomo de nitrogeno al que están unidos pueden formar un anillo de cuatro a siete eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S; o uno de R7 y R8 y uno de R5 y R6 unto con los átomos a los que están unidos pueden formar un anillo de cuatro a siete eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S; o uno de R7 y R8 junto con Rd y los átomos a los que están unidos pueden formar un anillo de cuatro a siete eslabones opcionalmente sustituido que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S; o uno de R7 y R8 y uno de Re y Rf junto con los átomos a los que están unidos pueden formar un anillo de cuatro a siete eslabones que contiene opcionalmente un heteroátomo adicional elegido entre O, N y S.
ARP060102971A 2005-07-13 2006-07-11 Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento AR056418A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69943505P 2005-07-13 2005-07-13

Publications (1)

Publication Number Publication Date
AR056418A1 true AR056418A1 (es) 2007-10-10

Family

ID=37054633

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102971A AR056418A1 (es) 2005-07-13 2006-07-11 Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento

Country Status (16)

Country Link
US (1) US7582760B2 (es)
EP (1) EP1904483A1 (es)
JP (1) JP2009501184A (es)
KR (1) KR100983752B1 (es)
CN (1) CN101263136A (es)
AR (1) AR056418A1 (es)
AU (1) AU2006268713A1 (es)
BR (1) BRPI0613430A2 (es)
CA (1) CA2615007A1 (es)
IL (1) IL188486A0 (es)
MX (1) MX2008000411A (es)
NO (1) NO20080110L (es)
RU (1) RU2415138C2 (es)
TW (1) TW200738697A (es)
WO (1) WO2007006677A1 (es)
ZA (1) ZA200800213B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2301625B1 (en) * 2004-09-30 2017-07-19 F. Hoffmann-La Roche AG Compositions and methods for treating cognitive disorders
US8173813B2 (en) 2007-03-23 2012-05-08 Neuraxon, Inc. Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity
RU2009139074A (ru) 2007-03-23 2011-04-27 Эбботт Гмбх Унд Ко.Кг (De) Азетидиновые соединения, подходящие для лечения расстройств, чувствительных к модуляции сеотонинового 5-нт6-рецептора
CN102153538B (zh) * 2010-02-11 2013-12-11 山东轩竹医药科技有限公司 苯并环衍生物
JP6515175B2 (ja) 2014-07-08 2019-05-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. 芳香族ヘテロ環誘導体及びその医薬的適用
CN108349944B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
CN107118161B (zh) * 2017-05-05 2019-12-31 湖北工业大学 2-正丙基-4-甲基苯并咪唑-6-羧酸的合成方法
EP3530651A1 (en) * 2018-02-21 2019-08-28 Adamed sp. z o.o. Indole and benzimidazole derivatives as dual 5-ht2a and 5-ht6 receptor antagonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510112A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du 2-oxo-pyrid-3-yl ou piperidin-3-yl indole, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
FR2621586B1 (fr) 1987-10-08 1990-02-02 Roussel Uclaf Nouveaux derives de l'azapirodecane, leur procede de preparation et leur application comme medicaments
TW203049B (es) 1990-04-13 1993-04-01 Yamanouchi Pharma Co Ltd
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
FR2667068B1 (fr) * 1990-09-26 1994-09-09 Adir Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5834587A (en) * 1996-10-08 1998-11-10 Smithkline Beecham Corporation G-protein coupled receptor, HLTEX 11
WO1999037643A1 (fr) 1998-01-26 1999-07-29 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives heterocycliques a fusion benzenique ou sels de ceux-ci
US6310066B1 (en) * 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
AR015036A1 (es) 1998-04-29 2001-04-11 American Home Prod Derivados de indolilo antisicoticos, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
US20020019395A1 (en) 2000-02-01 2002-02-14 Bing-Yan Zhu Indalone and benzimidazolone inhibitors of factor Xa
EP1272483A2 (en) 2000-03-24 2003-01-08 Millenium Pharmaceuticals, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
ES2253370T3 (es) 2000-04-21 2006-06-01 PHARMACIA & UPJOHN COMPANY LLC Cabergolina para el tratamiento del sindrome de fibromialgia y de fatiga cronica.
AR033520A1 (es) 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
US6440096B1 (en) * 2000-07-14 2002-08-27 Becton, Dickinson And Co. Microdevice and method of manufacturing a microdevice
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
WO2004026837A2 (en) 2002-09-18 2004-04-01 Eli Lilly And Company Histamine h3 receptor antagonists, preparaton and therapeutic uses
CA2502729A1 (en) 2002-10-25 2004-05-06 Haiyan Wu Use of heterocyclic amine-type compounds as neuroprotective agents
ES2298609T3 (es) * 2002-11-08 2008-05-16 F. Hoffmann-La Roche Ag Benzoxazinonas sustituidas y usos de las mismas.
MXPA06000700A (es) * 2003-07-23 2006-04-11 Wyeth Corp Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
MXPA06000701A (es) * 2003-07-23 2006-04-11 Wyeth Corp Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
EP1708713B1 (en) * 2004-01-16 2008-03-12 F. Hoffmann-la Roche AG 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d)(1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system
EP2301625B1 (en) * 2004-09-30 2017-07-19 F. Hoffmann-La Roche AG Compositions and methods for treating cognitive disorders
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors

Also Published As

Publication number Publication date
CN101263136A (zh) 2008-09-10
EP1904483A1 (en) 2008-04-02
NO20080110L (no) 2008-04-11
US7582760B2 (en) 2009-09-01
RU2008100081A (ru) 2009-08-20
KR20080019286A (ko) 2008-03-03
TW200738697A (en) 2007-10-16
AU2006268713A1 (en) 2007-01-18
IL188486A0 (en) 2008-04-13
BRPI0613430A2 (pt) 2011-01-11
CA2615007A1 (en) 2007-01-18
MX2008000411A (es) 2008-03-10
WO2007006677A1 (en) 2007-01-18
KR100983752B1 (ko) 2010-09-24
ZA200800213B (en) 2008-12-31
US20070015744A1 (en) 2007-01-18
JP2009501184A (ja) 2009-01-15
RU2415138C2 (ru) 2011-03-27

Similar Documents

Publication Publication Date Title
AR056418A1 (es) Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
ATE556058T1 (de) 1-(2h)-isochinolonderivat
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR057769A1 (es) Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
RU2015148006A (ru) Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv
AR060173A1 (es) Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc.
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR049346A1 (es) 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas
CO6150145A2 (es) Derivados de aril/heterociclo/cicloalquil/cicloalquil fenil substituidos utiles como agentes inmunosupresores
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
AR081649A1 (es) Compuestos heteroarilo nitrogenados
AR054890A1 (es) Derivados de quinolina como agentes antibacterianos
AR064414A1 (es) Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
NO20080871L (no) N-(Heteroaryl)-1-heteroarylalkyl-1 H-indol-2-karboksamidderivater, fremstilling og terapeutisk anvendelse derav
ES2612921T3 (es) Compuestos de difluorolactama como agonistas selectivos del receptor EP4 para su uso en el tratamiento de enfermedades y afecciones mediadas por EP4
AR065891A1 (es) Derivados de piridina y pirimidina como antagonistas del mglur2
AR039988A1 (es) Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos
PE20061362A1 (es) Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion
AR063636A1 (es) Derivados de indol y de benzofurano-2-carboxamida
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal